The FDA extended Exelixis’ review of zanzalintinib with atezolizumab for metastatic colorectal cancer by three months. The updated March 3, 2027 action date gives investors the next stated regulatory milestone after Exelixis submitted safety and efficacy data that the agency classified as a major amendment.
Key Highlights
- The agency classified Exelixis’ updated safety and efficacy data as a major amendment.
- The updated PDUFA action date is March 3, 2027, for zanzalintinib with atezolizumab in metastatic colorectal cancer.
- The FDA requested information, and Exelixis submitted updated safety and efficacy data.
EXELIXIS, INC. (NASDAQ: EXEL) said the FDA extended its review of zanzalintinib with atezolizumab for metastatic colorectal cancer by three months.
Updated Safety And Efficacy Data
The application covers zanzalintinib in combination with atezolizumab for patients with metastatic colorectal cancer. Exelixis submitted updated safety and efficacy information after an FDA information request. The agency designated that updated submission a major amendment. The FDA’s notification on September 10, 2026 concerned the new drug application and the review period attached to that application. Brenda J. Hefti signed the update on September 11, 2026 as senior vice president and general counsel.
March 3, 2027 FDA Milestone
The filing identifies the updated PDUFA action date as March 3, 2027. The FDA extended the review period by three months. The FDA deemed the updated safety and efficacy data a major amendment. The FDA review concerns the zanzalintinib and atezolizumab combination for metastatic colorectal cancer.
FAQs
Q: Why did the FDA extend Exelixis zanzalintinib review?
A: The FDA requested information, and Exelixis submitted updated safety and efficacy data. The agency classified that submission as a major amendment, extending review by three months.
Q: What is Exelixis’ updated FDA action date for zanzalintinib?
A: The updated PDUFA action date is March 3, 2027. It applies to zanzalintinib with atezolizumab for metastatic colorectal cancer under review.
Q: What does the Exelixis FDA update mean for investors?
A: The FDA extended the review period by three months and set an updated PDUFA action date of March 3, 2027. The review concerns zanzalintinib with atezolizumab for metastatic colorectal cancer.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.